Picture of Verbio SE logo

VBK — Verbio SE News Story

0.000.00%
de flag iconLast trade - 00:00
EnergyHighly SpeculativeMid CapFalling Star

Germany's Verbio reports 18.9% revenue rise in H1

Overview

Germany biofuels producer's H1 revenue rose 18.9% yr/yr to EUR 893.7 mln

EBITDA for H1 increased to EUR 45.5 mln, driven by Bioethanol/Biomethane segment

Company returned to positive free cash flow in Q2, firming up FY 2025/26 forecast

Outlook

Verbio firms up FY 2025/26 EBITDA forecast at upper end of previous range

Company expects moderate reduction in net financial debt for FY 2025/26

Regulatory changes in Germany to impact biofuels market and GHG quota prices

Result Drivers

PRODUCTION INCREASE - Higher production volumes in Bioethanol/Biomethane segment due to ramp-up in North America and expanded capacity in South Bend

GHG QUOTA MARKET - Recovery of GHG quota market led to higher quota prices, boosting revenues

COST MANAGEMENT - Disproportionately low increase in raw material costs relative to revenue contributed to improved gross margin

Key Details

MetricBeat/MissActualConsensus Estimate
H1 SalesEUR 893.70 mln
H1 EBITDAEUR 45.50 mln
H1 EBITDA Margin5.10%
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell" The average consensus recommendation for the renewable fuels peer group is "buy" Wall Street's median 12-month price target for Verbio SE is €24.50, about 4.5% below its February 11 closing price of €25.66 The stock recently traded at 47 times the next 12-month earnings vs. a P/E of 81 three months ago Press Release: ID:nEQ9QSFrca For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Verbio SE

See all news